Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights Journey Medical (Nasdaq: DERM) reported full-year 2025 results and corporate highlights on March 25, 2026. Total revenues were $61.9 million, up 10% from $56.1 million in 2024, driven by the commercial launch of Emrosi™ (net revenues $14.7 million; ~53,000 prescriptions).Gross margin improved to 66.2%, Adjusted EBITDA was $2.9 million, cash was approximately $24.1 million, and working capital was $29.4 million. Net loss narrowed to $11.4 million (−$0.47/share).

#DERM #FBIO Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/DERM/journey-medica...

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET; registration is available online and the replay will remain available about 30 days.

#DERM #FBIO Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

www.stocktitan.net/news/DERM/journey-medica...

Te lo contamos en esta publicación y si quieres saber más, puedes conocer los resultados obtenidos en: seo.org/biodiversida...

#PRTR #ProyectosPRTR #FBio #NextGenerationEU #MITECO @fbiodiversidad.bsky.social

Destacamos lo fundamental que es la colaboración entre distintos actores y compromiso por parte de las administraciones para no perder los castañares y avellanares.

#PRTR #ProyectosPRTR #FBio #NextGenerationEU #MITECO @fbiodiversidad.bsky.social

Hoy estamos presentando el trabajo realizado bajo el sello de #MontesVivos.

Estamos muy contentos de poder compartir las conclusiones y aprendizajes obtenidos del trabajo de los 2 últimos años.

#PRTR #ProyectosPRTR #FBio #NextGenerationEU #MITECO
@fbiodiversidad.bsky.social

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights  Fortress Biotech (NASDAQ: FBIO) reported Q3 2025 total net revenue of $17.6M, a 20.5% increase versus Q3 2024, driven largely by Journey Medical dermatology sales. Journey Medical net product revenue was $17.0M in the quarter vs. $14.6M a year earlier. Fortress reported consolidated net income of $3.7M ($0.13 basic, $0.11 diluted) versus a loss of $(15.0)M in Q3 2024. Consolidated cash totaled $86.2M as of Sept 30, 2025, up $28.9M year-to-date. Corporate updates include Sun Pharma's acquisition of Checkpoint (Fortress received ~$28M upfront plus potential CVR and a 2.5% royalty), dotinurad entering two Phase 3 trials, and an FDA CRL for CUTX-101 citing manufacturing (cGMP) observations with a planned resubmission.

#FBIO #FBIOP Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 

www.stocktitan.net/news/FBIO/fortress-biote...

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Journey Medical (Nasdaq: DERM) reported Q3 2025 net revenues of $17.6 million, a 21% year-over-year increase driven by the U.S. commercial launch of Emrosi. Emrosi generated $4.9 million in net sales and prescriptions rose 146% sequentially versus Q2 2025. Gross margin improved sequentially in 2025 to 67.4% in Q3. Net loss narrowed to $2.3 million (or $(0.09) per share). Adjusted EBITDA was positive $1.7 million. Cash and cash equivalents totaled $24.9 million at September 30, 2025. Management hosted a conference call on November 12, 2025 to discuss results and recent clinical and commercial highlights.

#DERM #FBIO Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/DERM/journey-medica...

Pomerantz Law Firm Investigates Fortress Biotech Amid Declining Stock Prices Pomerantz Law Firm is looking into claims of potential securities fraud by Fortress Biotech following a significant drop in stock value. Join the class action.

Pomerantz Law Firm Investigates Fortress Biotech Amid Declining Stock Prices #USA #New_York #Pomerantz_LLP #Fortress_Biotech #FBIO

Pomerantz Law Firm Investigates Fortress Biotech Inc. Due to Allegations of Securities Fraud Pomerantz LLP opens an investigation into Fortress Biotech Inc. for potential securities fraud amid stock price drop following FDA's Complete Response Letter.

Pomerantz Law Firm Investigates Fortress Biotech Inc. Due to Allegations of Securities Fraud #USA #New_York #Fortress_Biotech #Pomerantz_LLC #FBIO

Pomerantz Law Firm Launches Investigation for Fortress Biotech Investors Amid Potential Fraud Concerns Pomerantz LLP is probing into fraud claims concerning Fortress Biotech Inc. after significant stock drops following a FDA letter. Contact them for more information.

Pomerantz Law Firm Launches Investigation for Fortress Biotech Investors Amid Potential Fraud Concerns #USA #New_York #Pomerantz_LLP #Fortress_Biotech #FBIO

Pomerantz Law Firm Investigates Fortress Biotech Inc. on Behalf of Investors Following FDA Concerns Pomerantz LLP is reviewing potential claims for Fortress Biotech investors after FDA issues surrounding CUTX-101 led to a significant stock drop.

Pomerantz Law Firm Investigates Fortress Biotech Inc. on Behalf of Investors Following FDA Concerns #USA #New_York #Pomerantz_LLP #Fortress_Biotech #FBIO

Trade Alerts, Wednesday October 1, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading Wed Oct 1st - #DKI #CETY #RITR #MSPR #FBIO #CHR - More: crystalequityresearch.com/trade-alerts... - #smallcap

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) relating to the

#FBIO #FBIOP Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

www.stocktitan.net/news/FBIO/fortress-biote...

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Fortress Biotech (NASDAQ:FBIO) reported significant Q2 2025 milestones and financial results. The company's subsidiary Checkpoint Therapeutics was acquired by Sun Pharma, generating ~$28 million upfront with potential for an additional $4.8 million CVR payment and 2.5% royalties on UNLOXCYT™ sales.Key highlights include: FDA acceptance of CUTX-101's NDA with PDUFA date of September 30, 2025, commercial launch of Emrosi™ for rosacea treatment with expanded payer coverage reaching 65% of U.S. commercial lives, and consolidated net revenue of $16.4 million in Q2 2025. The company reported net income of $13.4 million ($0.50 per share basic).Cash position strengthened to $74.4 million as of June 30, 2025, up from $57.3 million at end of 2024. Journey Medical's product revenues reached $15.0 million in Q2 2025.

#FBIO #FBIOP Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

Journey Medical Hits Major Milestone: New Rosacea Drug Launch Drives Path to Profitability Journey Medical marks 4 years on Nasdaq with Emrosi rosacea treatment launch showing strong initial revenue. Company targets positive EBITDA milestone. Get details.

#DERM #FBIO Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

www.stocktitan.net/news/DERM/journey-medica...

Major Insurance Victory: Emrosi Rosacea Drug Now Covered for 121 Million Americans, More Than Doubles Previous Access Journey Medical's Emrosi sees dramatic insurance coverage jump from 29% to 65% of commercial lives. New rosacea treatment now accessible to millions more patients. Learn more.

#DERM #FBIO Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

www.stocktitan.net/news/DERM/journey-medica...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Jul 9th - #VACH #SEAT #PHH #NCNA #MITK #KRNY #GROW #FBIO #EOSE #DENN #BCTX #AIXI #PSFE #HCI #CBL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Journey Medical Achieves Major Milestone: Added to Both Russell 2000 and 3000 Indices Following Successful Drug Launch Journey Medical secures spots in prestigious Russell indices amid strong Emrosi launch. See how this pharma company's market presence is expanding. Get details.

#DERM #FBIO Journey Medical to Join Russell 2000® and Russell 3000® Indexes

www.stocktitan.net/news/DERM/journey-medica...

Breakthrough Rosacea Treatment Emrosi Showcases Lowest-Dose Minocycline on Lifetime TV Special Discover how Emrosi's unique lowest-dose minocycline formulation transforms rosacea treatment. Featured on Lifetime's The Balancing Act with expert insights. Learn more.

#DERM #FBIO Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

www.stocktitan.net/news/DERM/journey-medica...

Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch Q1 results reveal $91.3M cash position, Checkpoint acquisition by Sun Pharma, FDA priority review for Menkes disease drug, and successful Emrosi launch. Get details.

#FBIO #FBIOP Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Journey Medical Corporation (NASDAQ: DERM) reported its Q1 2025 financial results, highlighting total net product revenues of $13.1 million, consistent with $13.0 million in Q1 2024. The company successfully launched Emrosi™, their new oral rosacea treatment, contributing $2.1 million in incremental revenue. The company's gross margin improved to 64% from 54% year-over-year.Key financial metrics include a reduced net loss of $4.1 million ($0.18 per share) compared to $10.4 million ($0.53 per share) in Q1 2024. Cash position strengthened to $21.1 million as of March 31, 2025. The company reported no R&D costs in Q1 2025, down from $7.9 million in Q1 2024, while SG&A expenses increased by $2.1 million due to Emrosi launch activities.Notable achievements include the publication of Emrosi's Phase 3 trial results in JAMA Dermatology, showing superiority over Oracea® and placebo, and its inclusion in the National Rosacea Society's Treatment Algorithms.

#DERM #FBIO Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/DERM/journey-medica...

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates Checkpoint Therapeutics (NASDAQ: CKPT) announced its Q1 2025 financial results and significant corporate updates. The company achieved a major milestone with the FDA approval of UNLOXCYT™ (cosibelimab-ipdl) in December 2024, becoming the first and only PD-L1 blocking antibody approved for treating advanced cutaneous squamous cell carcinoma. In March 2025, Checkpoint entered into a merger agreement with Sun Pharmaceutical Industries, valued at up to $416 million, with the special stockholder meeting scheduled for May 28, 2025.Financial highlights for Q1 2025 include: cash position increased to $33.0 million from $6.6 million in Q4 2024; R&D expenses decreased to $3.8 million from $8.5 million year-over-year; G&A expenses increased to $7.4 million from $2.5 million; and net loss was $11.2 million ($0.19 per share) compared to $10.9 million ($0.33 per share) in Q1 2024.

#CKPT #FBIO Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

www.stocktitan.net/news/CKPT/checkpoint-the...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish Moving Average Convergence Divergence Crossovers, Mon May 12th - #VACH #REAL #OMEX #METCB #KOD #JAGX #INVA #FBIO #ABAT #WBX #SKE #LFT #EVH #ARMN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 Journey Medical Corporation (NASDAQ: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after U.S. market close.The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be accessible through Journey Medical's website and will remain available for approximately 30 days after the call.

#DERM #FBIO Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

www.stocktitan.net/news/DERM/journey-medica...

Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings Fortress lands FDA approvals for Emrosi and UNLOXCYT, secures $28M Sun Pharma deal, while streamlining operations. See full analysis of strategic transformation.

#FBIO #FBIOP Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

Breakthrough: CKPT Secures FDA Approval and $416M Merger Deal in Transformative Year First PD-L1 treatment approved for advanced skin cancer, plus strategic merger with Sun Pharma. See full analysis of CKPT's milestone achievements and financial outlook.

#CKPT #FBIO Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

www.stocktitan.net/news/CKPT/checkpoint-the...

FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance Journey Medical secures FDA approval for Emrosi rosacea treatment, reports $56.1M revenue. Early prescriptions signal strong market entry. Full promotion starts April 2025.

#DERM #FBIO Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/DERM/journey-medica...

Journey Medical Sets Date for 2024 Annual Results: Dermatology Leader's Financial Update Journey Medical, a dermatological pharma leader, announces earnings call with management discussion. Join the webcast to hear full-year performance and strategic outlook.

#DERM #FBIO Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

www.stocktitan.net/news/DERM/journey-medica...

AI Breakthrough: Fortress Biotech's New Partnership Transforms Drug Development Process Fortress Biotech leverages Partex's AI platform to revolutionize drug asset evaluation, accelerating development pipeline while two approved drugs generate revenue.

#FBIO #FBIOP Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

www.stocktitan.net/news/FBIO/partex-and-for...

Sun Pharma to Acquire Checkpoint Therapeutics Sun Pharma has announced the acquisition of Checkpoint Therapeutics (CKPT) in a deal valued at up to $355 million, offering $4.10 per share in upfront cash payment plus a contingent value right of up to $0.70 per share. The acquisition centers on UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).The deal represents a 66% premium to Checkpoint's closing price on March 7, 2025. The transaction, expected to close in Q2 2025, requires stockholder and regulatory approvals. Checkpoint reported minimal revenue of $0.04 million and a net loss of $27.3 million for the nine months ending September 2024, with R&D expenses of $19.3 million.Fortress Biotech, Checkpoint's controlling stockholder, will receive royalty payments based on future cosibelimab sales and has agreed to vote in favor of the transaction.

#CKPT #FBIO Sun Pharma to Acquire Checkpoint Therapeutics

www.stocktitan.net/news/CKPT/sun-pharma-to-...